DOACs for stroke prevention in patients with AF and cancer.
atrial fibrillation
cancer
direct oral anticoagulants (DOACs)
Journal
The British journal of cardiology
ISSN: 1753-4313
Titre abrégé: Br J Cardiol
Pays: England
ID NLM: 9503762
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
24
6
2022
pubmed:
2
12
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Stroke prophylaxis in atrial fibrillation is an important consideration in patients with cancer. However, there is little consensus on the choice of anticoagulation, due to the numerous difficulties associated with active cancer. Direct oral anticoagulants (DOACs) have been shown to be a promising option. Here, we conduct a simple cross-sectional analysis of 29 cancer patients receiving DOACs for stroke prophylaxis in atrial fibrillation at a tertiary-care institution in London. Our study demonstrates an encouraging efficacy and safety profile of DOACs used in this setting. We conclude by suggesting that, while DOACs may be useful, anticoagulation in cancer patients should continue to be individualised.
Identifiants
pubmed: 35747222
doi: 10.5837/bjc.2020.036
pii: bjc.2020.036
pmc: PMC9205240
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Informations de copyright
Copyright © 2020 Medinews (Cardiology) Limited.
Déclaration de conflit d'intérêts
None declared.
Références
J Am Heart Assoc. 2018 Aug 21;7(16):e008987
pubmed: 30369307
J Am Coll Cardiol. 2018 Oct 16;72(16):1913-1922
pubmed: 30309468
J Thromb Haemost. 2019 Aug;17(8):1247-1252
pubmed: 31207027
Blood Adv. 2018 Feb 13;2(3):200-209
pubmed: 29378726
J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349
pubmed: 30898209